Sanofi seeks service providers to develop an AI-driven platform for Cancer & Immunology treatments
Key Insights and Signals – Hospital & Healthcare
Centre Setup Beebe offers lab services in Milford Beebe will offer a variety of services, including simple blood tests, X-rays, and treatment for eye and ear infections, sinus infections, sprains, and rashes, among others. Read More>> Western Dental inaugurates new Colton and Glendale offices in Southern California The newly constructed offices are equipped with state-of-the-art technology and supported by experienced family dentists and specialists, creating a full-service dental home. Read More>>Merger and Acquisition BayCare acquires Northside Behavioral Health Center With this acquisition, BayCare expands its commitment to Behavioral Health and aims to provide individuals and families access to affordable and quality behavioral healthcare. Read More>>New Product Development Tryp Therapeutics, Massachusetts General Hospital to conduct Phase 2 Psilocybin trials The Phase 2 clinical trials will assess the effects of psilocybin-assisted psychotherapy in the treatment of adult patients with irritable bowel syndrome. Read More>>Partnerships Mayo Clinic’s new partnership targets AR for surgical navigation Mayo Clinic will provide clinical, technological, and research assistance to AR Medtech company MediView XR to enhance and advance 3D X-ray surgical navigation technology. Read More>> LCMC Health and Tulane University finalize partnership This partnership expands access to comprehensive and specialized care and boosts innovation and training while enriching the communities in New Orleans and Southeast Louisiana. Read More>>Executive Movements Cleveland Clinic London names Chief Nursing Officer Sheila Miller, DNP, RN, brings over 35 years of nursing experience to her role when she starts in February. Most recently, Dr. Miller was CNO at Cleveland Clinic Akron General. Read More>> Professional Emmanuel Hirsch appointed as Ethics VP of the Orpea Group Drawing support from an Ethics Advisory Board currently being set up, Mr. Hirsch will be responsible for implementing and coordinating the renewal of the ethics policy. Read More>> Cincinnati Children’s names Chief Strategy Officer Veteran leader Oliver Rhine was promoted to Senior VP and CSO. Mr. Rhine has held many leadership roles in the last decade, including VP of Strategic Planning very recently. Read More>>
Key Insights and Signals in Medical Devices
Product Launch Carestream unveils next-gen detector in Long-Length Digital Imaging It captures long-bone and spine images with a single exposure, making it ideal for pediatric imaging and long-bone and spine images of people with limited mobility. Read More>> Sonova launches new earbuds, expanding into the early entry hearing solutions category The company launched Sennheiser Conversation Clear Plus earbuds, a new speech-enhanced hearable to help consumers improve their comprehension in noisy environments. Read More>>Partnership ASLAN and Thermo Fisher Scientific to manufacture Eblasakimab for Phase 3 trials The companies will produce high-concentration Eblasakimab for Phase 3 clinical studies. Eblasakimab is a first-in-class monoclonal antibody that might treat atopic dermatitis (AD). Read More>>Merger and Acquisition Heska Corporation completes acquisition of LightDeck Diagnostics The acquisition represents a key advancement in the company’s strategic plan to accelerate research and development and manufacturing capabilities at scale. Read More>>Executive Movement GE HealthCare appoints Taha Kass-Hout as CTO Dr. Kass-Hout will help advance GE HealthCare’s D3 precision care strategy, a framework, and digital solutions highlighting the company’s smart devices. Read More>> Beta Bionics appoints Dr. Steven Russell as Chief Medical Officer The appointment comes ahead of the commercial launch of the iLet Bionic Pancreas System. Dr. Russell is an endocrinologist and diabetologist with 20 years of experience with diabetes. Read More>>Financial and Market Activity QuidelOrtho reports preliminary revenue results for Q4 and full year 2022 The company expects total revenues to be in the range of USD 853 Mn to USD 868 Mn. The preliminary unaudited figures are based on management’s analysis for Q4 and the full year. Read More>> Intuitive Surgical says ‘expect revenue growth to stay slow’ The company reported selling 305 da Vinci systems, down 9% from 336 in Q3 2021. Revenue from the sale of systems was USD 426 Mn, up 3% from USD 415 Mn a year earlier. Read More>>
Key Insights and Signals in Pharmaceutical
Product Launch Cipla Health forays into consumer skincare by launching Rivela Dermascience Rivela Dermascience products are dermatologically tested on Indian skin in leading labs in the country for their efficacy and safety against any allergies or reactions. Read More>>New Product Development Horizon Therapeutics enrolls first patient in Phase 2 trial of Daxdilimab for DLE The first patient has enrolled in a Phase 2, placebo-controlled study to test Daxdilimab, a human monoclonal antibody to treat primary discoid lupus erythematosus (DLE). Read More>>Centre Setup and Expansion Cold Spring Harbor Laboratory’s USD 57 Mn Neuroscience Research Complex Breaks Ground on Long Island The complex will add three new buildings and more than 36,000 square feet of research facilities to the campus for researching developmental neurological disorders. Read More>>Deal Hikma and Celltrion Healthcare sign a new exclusive licensing agreement Celltrion Healthcare will develop and supply Vegzelma (CT-P16, bevacizumab) while Hikma will be responsible for the commercialization of the product in all its MENA markets. Read More>>Merger and Acquisitions Moderna to acquire OriCiro Genomics for USD 85 Mn With this acquisition, Moderna will obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing. Read More>> Viatris closes acquisitions of Oyster Point Pharma and Famy Life Sciences The company acquired Oyster Point Pharma for approximately USD 415 Mn in cash upfront, which includes the USD 11 per share paid to stockholders. Read More>>Partnerships Gilead and EVOQ Therapeutics announce collaboration to advance Immunotherapies The companies will advance EVOQs proprietary technology for treating rheumatoid arthritis (RA) and lupus. This transaction will have a minimal financial impact on Gilead’s GAAP and non-GAAP EPS. Read More>> Applied Therapeutics, Advanz Pharma partner to Commercialize AT-007 in Europe The partnership will have a strategic focus on the commercialization of specialty, hospital, and rare disease medicines, including the commercialization of AT-007 in Europe. Read More>>Executive Movements MacroGenics appoints Dr. Margaret Liu and Meenu Chhabra Karson to the Board Dr. Liu will serve as a member of the MacroGenics Science and Technology Committee, and Ms. Karson will serve as a member of the company’s Audit Committee. Read More>> Boris Dbler appointed as CFO by STADA Boris Dbler has been named Group CFO of STADA Arzneimittel AG effective January 1, 2023, by the Supervisory Board. Since August 2022, Dbler has served as STADA’s interim CFO. Read More>> Viatris appoints Scott A. Smith and Elisha W. Finney to the Board In addition to this, Smith is also Chairman of the board of Triumvira Immunologics and a member of the Apexigen and Refuge Biotechnologies boards of directors. Read More>>
Did you find the newsletter helpful? *|SURVEY: Yes|* *|SURVEY: No|*
Latest Industry Insights from Draup Braindesk
Antibody Technology Platform
Sanofi wants to build an IgM antibody platform to target three cancer and three immunology/inflammation targets.
It focuses on antibody-drug conjugates (ADC) technology to deliver potent anti-cancer drugs to tumor cells expressing a specific protein.
The technology provides various treatment modalities, including monoclonal and bispecific antibodies.
Sanofi develops oncology medications and unique therapies for patients with myeloma, lung, and breast cancer.
Sanofi is committed to developing CRISPR genome editing technologies that allow genetic modification of novel natural killer (NK) cell cancer therapies.
This therapy offers a variety of alternative treatments, including monoclonal and bispecific antibodies.
AI-Driven Cancer & Immunology Medicines
Sanofi is creating an AI-driven platform for cancer and immunology treatments. This platform improves digital precision medicine and drug quality for patient health.
Service Providers with rich expertise in AI-Driven Cancer and Immunology Medicines would be apt to serve Sanofi with better solutions.
Digital Healthcare Solution
Sanofi wants to establish a digital medical practice platform using data and AI (AI). This platform improves illness identification and enables enhanced patient therapies.
Sanofi plans to monitor patient data using a digital platform to identify and cure disorders as they occur.
Service Providers with rich expertise in Digital Healthcare solutions would be apt to serve Sanofi with better solutions.
Company – Onkos Surgical Total Funding– USD 74.17 Mn About: Onkos Surgical is a privately-held surgical oncology company that brings new technology and solutions to surgical oncologists. It aims at redefining musculoskeletal oncology and complex orthopedics through a surgeon-driven, patient-inspired approach. Read More>>
Latest Reports Published in Draup
Hologic Account Intelligence Report
Hologic intends to launch enhanced diagnostics tools to detect viruses, pre-cancerous lesions, and cervical cancer cells in patients. Read More>>
Invacare Corporation Account Intelligence Report
The company is expanding its offerings to the respiratory segment by providing a remote monitoring solution and mobile application to enhance patient safety. Read More>>
Here’s what’s new on our Sales Intelligence Platform Introducing Guest Users
Make collaboration with your colleagues a breeze! Invite your colleagues to Draup as Guest Users and collaborate on projects. Guests are above and beyond your allowed Draup licenses and free of charge (up to 5 guests per paid license). The guest users will have access to My Leads and Signals features in Draup.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
This website uses the following additional cookies:
Please enable Strictly Necessary Cookies first so that we can save your preferences!